Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study

Y.J. Kim; M. Kurosaki; K. Numata; H.Y. Lim; M. Ikeda; M. Kudo; Y-H. Huang; G. Shao; N. Kato; D-Y. Kim; S-B. Cho; C-H. Hsu; S-M. Lin; L-B. Jeng; K-K. Kuo; Y. Mao; B. Chewaskulyong; J. Khan; K. Ozgurdal; S. Qin

doi:10.1016/j.annonc.2022.10.109

YUHSpace

BROWSE

0 153

Cited 0 times in

Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study

Authors: Y.J. Kim ; M. Kurosaki ; K. Numata ; H.Y. Lim ; M. Ikeda ; M. Kudo ; Y-H. Huang ; G. Shao ; N. Kato ; D-Y. Kim ; S-B. Cho ; C-H. Hsu ; S-M. Lin ; L-B. Jeng ; K-K. Kuo ; Y. Mao ; B. Chewaskulyong ; J. Khan ; K. Ozgurdal ; S. Qin